Open AccessRadium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease
Author(s) -
Michael R. Harrison,
Daniel J. George,
Wong,
Andrew J. Armstrong
Publication year - 2013
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s25537
Subject(s) - medicine , prostate cancer , docetaxel , zoledronic acid , oncology , clinical trial , radium 223 , denosumab , bone metastasis , cancer , osteoporosis
Radium-223 chloride ((223)Ra; Alpharadin) is an alpha-emitting radioisotope that targets areas of osteoblastic metastasis and is excreted by the small intestine. When compared with beta-emitters (eg, strontium-89, samarium-153), (223)Ra delivers a high quantity of energy per track length with short tissue penetration.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom